Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.
about
Inhibition of ENaC by endothelin-1Pulmonary arterial hypertension: a comparison between children and adultsGiant, dissecting, high-pressure pulmonary artery aneurysm: case report of a 1-year natural courseThe right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.Severe pulmonary arterial hypertension associated with congenital cardiac shunts: evolution under specific treatment.Identifying "super responders" in pulmonary arterial hypertension.A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Perioperative management in patients with pulmonary hypertension.Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade.Expression pattern of endothelin system components and localization of smooth muscle cells in the human pre-ovulatory follicle.Prostacyclin: an inflammatory paradox.Overview of current therapeutic approaches for pulmonary hypertension.Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenolEffect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial.Response to bosentan in children with pulmonary hypertension.Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.When cure is care: diagnosis and management of pulmonary arterial hypertension.Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence.Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension.Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.Review of bosentan in the management of pulmonary arterial hypertensionMolecular pathogenesis of pulmonary arterial hypertensionPulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.Current therapies for pulmonary arterial hypertension.Applicability of bosentan in Dutch patients with Eisenmenger syndrome: preliminary results on safety and exercise capacity.Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.Expert opinion on available options treating pulmonary arterial hypertension.Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.Pharmacotherapy for meconium aspiration.Therapeutic advances in pulmonary arterial hypertension.Pulmonary hypertension-"state of the art" management in 2012.Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.Current and future therapy for pulmonary hypertension in patients with right and left heart failure.
P2860
Q27005957-72753D49-4363-4DB6-8C21-F9AB3B998D85Q27687320-71691A27-6530-4449-AD4E-D2D249FE55E8Q30502967-8301462F-37C1-41D6-9A11-F61A615DD471Q30585014-44237DC2-0C94-49A2-ADDA-88E8BE895A47Q33532813-E597C3DC-754D-404E-9E76-6BA6D3BB7794Q33645081-DE1D4604-5FDA-4E9C-8209-5D0F05079B4DQ33786574-94E3BE2F-00CD-407D-9D24-07839765E11CQ33788452-E89F5B50-5F09-4A45-B141-7F824A922654Q33797499-5715281C-47D1-4569-9172-80C1E13F9496Q33965837-14328D56-FDF1-4239-9859-6F7B22EFD837Q34276102-229A027E-8A46-4C4C-9565-146C720CF67FQ34815638-609BF74F-53A4-475E-8B98-32C902115BD9Q35025863-6DD50D54-5D79-4EB0-AB4F-0DE3F4FDCAF7Q35412362-09E7EA46-A085-4A37-ABCE-6822D07D251EQ35537385-D7FA8C42-ABAB-40BF-B8EC-A5F0EBEA9FF4Q35584906-CEE499CD-D060-4B93-B23F-C6B93F285BD2Q35768938-0EFE7773-00CA-4A12-804A-5313A56EAAAFQ35771679-4BDFCF00-C55E-44FB-8E1E-6E253177C361Q35773295-B6E5C768-A274-4E7A-A27C-BB3AFEDA0EBFQ36014079-0A97F1D3-06CA-4147-B402-C383D65BE8E3Q36062149-DFEBAD0F-4BAB-4CF6-B8F6-3C684FEAFADCQ36192759-61F6B741-76C9-466A-A674-4CE364BB2468Q36491793-75BA1AC3-77CE-4A66-9061-D06C57702934Q36577383-20E52AA8-EAE8-46C7-9965-080485454B6CQ36596818-8C3F8F14-54FE-4A6A-BD69-22AC299DBC51Q36736065-42AC84C0-C533-462C-9941-6221F41450B0Q36795578-E5D2B13D-75B5-41E5-94D0-F5EB5991E41EQ36834630-B8F658FC-9219-4083-95B8-C6D8CE418F8FQ36917342-E669E94F-A8F0-4146-A4BE-2BC537D0B74DQ36930712-51727F85-6839-409C-A624-AEC92127158FQ36932136-6CDFB7F2-978D-46C1-B818-44D5E0103113Q36967262-C0AAF014-F5C4-4B68-B1D8-A2F87C4E86BAQ37019838-FA0993EB-C184-46DF-8F5C-E66E2CFF228DQ37302470-CE365AFA-4C3E-4BD0-968B-5C980F202A11Q37341679-9333B08B-512D-4CD5-A2D6-80E3202CBCF6Q37362631-19249F00-0AFC-4EA0-94B1-1D0178451388Q37387305-B62CA35B-84A9-4D86-B8AB-7D63A3FAFB7EQ37403190-B9FDBB51-3F7E-41DA-97FD-486D6985ACC5Q37504296-B8A4E974-C38B-477C-A6FE-EF53A6AA4B4BQ37688167-8643662C-8A32-4347-A92E-75D119856C95
P2860
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Effects of the dual endothelin ...... ion: a 1-year follow-up study.
@en
Effects of the dual endothelin ...... ion: a 1-year follow-up study.
@nl
type
label
Effects of the dual endothelin ...... ion: a 1-year follow-up study.
@en
Effects of the dual endothelin ...... ion: a 1-year follow-up study.
@nl
prefLabel
Effects of the dual endothelin ...... ion: a 1-year follow-up study.
@en
Effects of the dual endothelin ...... ion: a 1-year follow-up study.
@nl
P2093
P356
P1433
P1476
Effects of the dual endothelin ...... ion: a 1-year follow-up study.
@en
P2093
Adaani Frost
David B Badesch
Gérald Simonneau
Ivan M Robbins
Lewis J Rubin
Olivier Sitbon
Richard N Channick
Victor F Tapson
P304
P356
10.1378/CHEST.124.1.247
P407
P577
2003-07-01T00:00:00Z